Empagliflozin

Dr. McPhee: This is not quite the best option in this case. Empagliflozin can an excellent drug, particularly for patients with certain co-morbidities, such as heart failure, chronic kidney disease, and established or high atherosclerotic cardiovascular (ASCVD) risk. It can also help when weight loss is a goal. There is no compelling cardiorenal indication to start it ahead of another drug that is more cost-effective and could also provide benefits in preventing complications and reducing weight.

Please go back and reconsider.

  • Verify patient identity and obtain e-consent before starting. [undo]
  • Allow the family member to stay on screen without clarifying their role [undo]
  • Use open-ended questions and clarify priority symptoms (pain, discharge, fever). [undo]
  • Ask rapid questions using medical jargon (ischemia, necrotic tissue, perfusion). [undo]
  • Ignore the wound complaint and focus solely on blood glucose. [undo]
  • Give an immediate diagnosis without exploring the patient’s narrative. [undo]
  • Connecting Care Virtually: Building Trust and Teamwork in Digital Health Communication [undo]
  • Privacy risk [undo]
  • new node [undo]
  • GP's routine visit [undo]
  • Βλέπεις τον ιατρικό της φάκελο [undo]
  • BrainHQ Συναισθηματικός παράγοντας [undo]
  • Root Node [undo]
  • STUCTURA ȘI FUNCȚIILE CELULEI [undo]
  • ΗΛΕΚΤΡΟΝΙΚΗ ΜΙΚΡΟΣΚΟΠΙΑ [undo]
  • go to espresso house [undo]
  • Furosemide (loop diuretic) [undo]
  • Examination [undo]
  • START [undo]
  • Bisoprolol (Beta-blocker) [undo]
  • Glycerol trinitrate (organic nitrate) [undo]
  • Dobutamine (beta agonist) [undo]
  • Empagliflozin [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21112
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway